XNAS
NXL
Market cap18mUSD
Jun 23, Last price
1.05USD
1D
0.96%
1Q
-51.39%
IPO
-37.87%
Name
Nexalin Technology Inc
Chart & Performance
P/E
—
P/S
108.40
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.83%
Rev. gr., 5y
-4.04%
Revenues
169k
+52.35%
Net income
-8m
L+63.64%
CFO
-4m
L+2.84%
Profile
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 169 52.35% | 111 -91.62% | 1,321 817.20% | |||
Cost of revenue | 7,923 | 7,729 | 4,552 | |||
Unusual Expense (Income) | ||||||
NOPBT | (7,755) | (7,618) | (3,230) | |||
NOPBT Margin | ||||||
Operating Taxes | (5) | 228 | ||||
Tax Rate | ||||||
NOPAT | (7,750) | (7,618) | (3,458) | |||
Net income | (7,607) 63.64% | (4,649) 141.39% | (1,926) -68.74% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 4,516 | 8,549 | ||||
BB yield | -17.76% | -156.64% | ||||
| Debt | ||||||
Debt current | 9 | 751 | ||||
Long-term debt | 4 | 60 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (3,480) | (3,031) | (6,183) | |||
| Cash flow | ||||||
Cash from operating activities | (3,944) | (3,835) | (2,216) | |||
CAPEX | ||||||
Cash from investing activities | (578) | 4,453 | (6,795) | |||
Cash from financing activities | 4,516 | (200) | 8,512 | |||
FCF | (7,740) | (7,621) | (4,297) | |||
| Balance | ||||||
Cash | 3,480 | 2,948 | 6,994 | |||
Long term investments | 96 | |||||
Excess cash | 3,471 | 3,039 | 6,928 | |||
Stockholders' equity | (84,632) | (77,031) | (72,346) | |||
Invested Capital | 88,308 | 80,190 | 78,580 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 9,216 | 7,357 | 7,287 | |||
Price | 2.76 581.82% | 0.40 -45.95% | 0.75 | |||
Market cap | 25,436 754.08% | 2,978 -45.43% | 5,458 | |||
EV | 21,956 | (53) | (726) | |||
EBITDA | (7,740) | (7,614) | (3,230) | |||
EV/EBITDA | 0.01 | 0.22 | ||||
Interest | 39 | 59 | ||||
Interest/NOPBT | ||||||